Status | Study |
Terminated |
Study Name: Everolimus in Treating Cutaneous T-cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2012-04-02 Interventions: Drug: Everolimus The study drug everolimus will be self-ad |
Completed |
Study Name: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Condition: Lymphoma, T-Cell, Cutaneous Date: 2011-11-29 Interventions: Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1 |
Completed |
Study Name: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) Condition: Lymphoma, T-Cell, Cutaneous Date: 2011-09-09 Interventions: Drug: placebo for SHAPE (SHP-141) |
No longer available |
Study Name: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Condition: Cutaneous T Cell Lymphoma Date: 2010-05-25 Interventions: Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated |
Completed |
Study Name: Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Condition: Refractory Cutaneous T-cell Lymphoma Date: 2009-11-03 Interventions: Drug: bexarotene 150 mg/m2/day |
Withdrawn |
Study Name: Trial of Curcumin in Cutaneous T-cell Lymphoma Patients Condition: Cutaneous T-cell Lymphoma Date: 2009-08-27 Interventions: Drug: Curcumin (Turmeric) |
Completed |
Study Name: Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Condition: Cutaneous T-Cell Lymphoma Date: 2008-10-22 Interventions: Drug: Tazarotene Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase |
Completed |
Study Name: A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2008-08-29 Interventions: Drug: Enzastaurin 1125 mg loading dose then 500 mg, oral, daily, until disease progression |
Completed |
Study Name: Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Condition: Cutaneous T-cell Lymphoma Date: 2007-11-05 Interventions: Drug: Pralatrexate Injection |
Completed |
Study Name: Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2007-06-21 Interventions: Drug: LBH589 Other Name: panobinostat |